Gyon Technologies Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Gyon Technologies Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-50,291	Closed	-$697K	–	292
2021 Q4	$697K	Buy	+50,291	New	+$666K	0.13%	220
2020 Q3	–	Sell	-88,244	Closed	-$420K	–	276
2020 Q2	$420K	Buy	+88,244	New	+$352K	1.02%	37
2020 Q1	–	Sell	-11,851	Closed	-$41K	–	107
2019 Q4	$41K	Buy	+11,851	New	+$29.8K	0.03%	128

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gyon Technologies Capital Management's BCRX Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2022, closing a stake of 50,291 shares — an estimated $697K sold.

Gyon Technologies Capital Management first reported a position in BCRX in Q4 2019 and held it in 3 quarters. The position peaked at $697K in Q4 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

Gyon Technologies Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Gyon Technologies Capital Management sold 50,291 BioCryst Pharmaceuticals shares in Q1 2022, an estimated $697K.
Gyon Technologies Capital Management first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Gyon Technologies Capital Management's BioCryst Pharmaceuticals position peaked at $697K in Q4 2021.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.